Tag: Sorrento Therapeutics Inc


Sorrento Therapeutics Inc (NASDAQ: SRNE) Proclaims Phase 2 Abivertinib Scientific Readings Have been Finished

Sorrento Therapeutics Inc (NASDAQ: SRNE) today broadcasted the conclusion of registration for its Phase 2 scientific pilot of Abivertinib in hospitalized COVID-19 patients in Brazil. This learning conclusion trails the lately finished registration of the U.S. Phase 2 scientific pilot. Statistics from the study is estimated to be accessible for […]